药物涂层球囊治疗下肢动脉硬化闭塞症的应用进展

Application progress of drug coated balloon in treatment of arteriosclerosis obliterans of lower extremity

关键词:  经皮腔内血管成形术  动脉硬化闭塞症  下肢  药物涂层球囊  再狭窄

Key words:  percutaneous transluminal angioplasty  arteriosclerosis obliterans  lower extremity  drug coated balloon  restenosis

摘要:

经皮腔内血管成形术(PTA)或支架置入术已被公认是治疗下肢动脉硬化闭塞症(LEASO)的重要方法，但术后再狭窄的发生限制了其疗效。药物涂层球囊(DCB)含有抗增殖药物，可以抑制新生血管内膜增生，降低再狭窄发生，从而克服了经皮腔内血管成形术的局限性。近年来的临床试验显示，DCB在治疗股腘动脉的初次病变及支架内再狭窄方面，可明显提高一期通畅率(PP)，降低晚期管腔损失(LLL)，但DCB在膝下动脉（BTK）中的治疗作用仍不明确。本文对DCB在治疗LEASO病变中的应用进展进行综述。

Abstract:

Percutaneous transluminal angioplasty (PTA) or stent implantation has been recognized as an important method in the treatment of lower extremity arteriosclerosis obliterans (LEASO), but restenosis is an important limiting factor. Drug coated balloon (DCB) contains antiproliferative drugs, which can inhibit neointimal hyperplasia and reduce restenosis, thus overcoming the limitation of percutaneous transluminal angioplasty. The main clinical trials published over the last 5 years showed that DCB significantly improved the primary patency (PP) and reduced late lumen loss (LLL) in the treatment of the primary and stent restenosis of the femoral popliteal artery. The role of DCB in the treatment of arteries below the knee(BTK）is still unclear. This article reviewed the application of DCB in the treatment of LEASO lesions.